EnzymeBioSystems (OTCBB:ENZB) recently made a spectacular move up off its $0.50 lows to the recent range of $2 a share.
On July 27 ENZB announced a preclinical methyl amooranin batch has been completed. Amooranin is the Company’s lead pharmaceutical product. EnzymeBioSystems plans to seek approval for the use of methyl amooranin in the prevention of breast cancer.
“We are pleased to announce that this preclinical batch of methyl amooranin has been completed,” stated Gary Rojewski, CEO of EnzymeBioSystems. He went on to say, “This batch will allow us to move forward in beginning to conduct the required toxicology rat studies for submitting an Investigational New Drug Application (“IND”) to the FDA.” He added, “We still need to produce a larger batch to complete the second species studies. Our initial work continues to demonstrate that methyl amooranin appears to be promising for the reduction of tumors.”
EnzymeBioSystems (OTCBB:ENZB) produces specialty enzymes and enzyme related products. The Company plans to use enzyme technologies to develop commercial solutions for different applications within the pharmaceutical industry.
ENZB, designed a drug delivery mechanism, whereby a series of semisynthetic penicillins and cephalosporins containing structural fragments of sarcomycin have been synthesized. Sarcomycin has been around for many years. It is an anti-tumor antibiotic. The problem, is that when it is taken by a cancer patients, and the sarcomycin is given alone, it does not attached to the tumor, but moves throughout the entire body. The penicillin delivers the sacromycin to the tumor where the penicillin attaches to the tumor as proteinase and delievers the sacromycin directly into the tumor.
The Company’s lead product is Amooranin which is isolated from the stem bark of the Indian medicinal plant Amoora rohituka, the product exhibits cytostatic as well as cytotoxic effects in human neoplastic hematopoetic and epithelial cells of diverse origin. Amoorain has also been shown to possess growth inhibitory and apoptosis-inducing effects in several mammary carcinoma cells of human origin.
In animal studies, AMR significantly inhibited the growth of xenografted SW 620 colon carcinoma in mice and reduced tumor size in in rats. Amoorain has also been shown to inhibit the growth of human acute lymphoblastic leukemia cells by pro-apoptotic mechanisms and improve the survival of mice bearing Dalton’s lymphoma ascites tumor cells.
EnzymeBioSystems has found a method for the synthesis of pure Amooranin. The discovery of the method for large-scale synthesis of Amoorain represents a key breakthrough as it eliminates the need of using plant material and hence the dependency on the nature. It also creates the opportunity for animal studies to explore the chemopreventive efficacy of Amooranin.
It is now the Company’s goal to complete animal testing of its synthetic Amooranin to demonstrate its efficacy and lack of toxicity. If the animal studies prove to be successful, the Company plans to submit an IND (Investigational New Drug) application with the FDA to begin Phase I human studies.
To Find out the inside Scoop on ENZB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On February 27 ENZB said it ”is a small company with a Big Pharma mentality. “The pharmaceutical industry has changed over the past decade. In the past, Big Pharma would spend a large amount of dollars in researching new pharmaceutical compounds. Today Big Pharma believes it to be more economical to purchase smaller companies that are working to develop and market novel products,” stated Ed Zimmerman, III CFO of EnzymeBioSystems.
The management and affiliates of EnzymeBioSystems have over 50-years of experience working for Big Pharma. This experience helps the company operate with the knowledge gained at Big Pharma.
Amooranin is the Company’s lead pharmaceutical product. Management believes the product can be used in the prevention of breast cancer and is working to obtain the necessary studies to apply for an Investigational New Drug for the product. Management has sourced the pre-clinical product batch and is negotiating with Contract Research Organizations (CRO) on the two species animal studies.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $62 million market valuation ENZB does have $344,000 in the treasury and little debt. They also have no revenues to date and are losing money. There was a significant promotion on this one featuring amateur landing pages that have come and gone since the run collapsed. We will be updating on ENZB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZB.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ENZB either long or short and we have not been compensated for this article.